These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 36888957)

  • 21. Collaborative Referral Model to Achieve Hepatitis C Micro-Elimination in Methadone Maintenance Treatment Patients during the COVID-19 Pandemic.
    Tai CM; Huang CK; Changchien TC; Lin PC; Wang DW; Chang TT; Chan HW; Chen TH; Tseng CH; Chen CC; Tsai CT; Sie YT; Yen YC; Yu ML
    Viruses; 2022 Jul; 14(8):. PubMed ID: 35893702
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatitis C elimination in Sweden: Progress, challenges and opportunities for growth in the time of COVID-19.
    Blach S; Blomé M; Duberg AS; Jerkeman A; Kåberg M; Klasa PE; Lagging M; Razavi-Shearer D; Razavi H; Aleman S
    Liver Int; 2021 Sep; 41(9):2024-2031. PubMed ID: 34051065
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estimating the Consensus hepatitis C Cascade of Care among people who inject drugs in Australia: Pre and post availability of direct acting antiviral therapy.
    Iversen J; Dore GJ; Starr M; Catlett B; Cunningham P; Geddes L; Maher L
    Int J Drug Policy; 2020 Sep; 83():102837. PubMed ID: 32645585
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Establishing a framework towards monitoring HCV microelimination among men who have sex with men living with HIV in Germany: A modeling analysis.
    Marquez LK; Ingiliz P; Boesecke C; Krznaric I; Schewe K; Lutz T; Mauss S; Christensen S; Rockstroh JK; Jain S; He F; Wertheim JO; Martin NK
    PLoS One; 2022; 17(5):e0267853. PubMed ID: 35551326
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Additional challenges in reaching hepatitis C elimination goals in Germany due to the COVID-19 pandemic - descriptive analysis of drug prescription data from January 2018 to June 2021.
    Meyer ED; Dudareva S; Kollan C; Mauss S; Wedemeyer H; Schmidt D; Zimmermann R
    Front Public Health; 2023; 11():1149694. PubMed ID: 37325322
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modelling the microelimination of chronic hepatitis C in the canton of Bern, Switzerland: Reaching the Swiss Hepatitis Strategy goals despite the impact of the COVID 19 pandemic.
    Schorr O; Blach S; Thurnheer C; Ruis C; Dufour JF
    PLoS One; 2022; 17(8):e0272518. PubMed ID: 35960770
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatitis C virus micro-elimination: Where do we stand?
    Mangia A; Cotugno R; Cocomazzi G; Squillante MM; Piazzolla V
    World J Gastroenterol; 2021 Apr; 27(16):1728-1737. PubMed ID: 33967553
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Telemedicine Chronic Viral Hepatitis C Treatment during the Lockdown Period in Romania: A Pilot Study.
    Doica IP; Florescu DN; Oancea CN; Turcu-Stiolica A; Subtirelu MS; Dumitra G; Rogoveanu I; Gheonea DI; Ungureanu BS
    Int J Environ Res Public Health; 2021 Apr; 18(7):. PubMed ID: 33916226
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Hepatitis C in a psychiatric setting: A forgotten reservoir?].
    Rolland B; Bailly F; Cutarella C; Drevon O; Carrieri P; Darque A; Hallouche N; Maptue N; Pol S; Llorca PM; Lang JP
    Encephale; 2021 Apr; 47(2):181-184. PubMed ID: 32473777
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness analysis of an active search to retrieve HCV patients lost to follow-up (RELINK-C strategy) and the impact of COVID-19.
    Vargas-Accarino E; Martínez-Campreciós J; Domínguez-Hernández R; Rando-Segura A; Riveiro-Barciela M; Rodríguez-Frías F; Barreira A; Palom A; Casado MÁ; Esteban R; Buti M
    J Viral Hepat; 2022 Jul; 29(7):579-583. PubMed ID: 35555847
    [No Abstract]   [Full Text] [Related]  

  • 31. Three Years of Progress Toward Achieving Hepatitis C Elimination in the Country of Georgia, April 2015-March 2018.
    Tsertsvadze T; Gamkrelidze A; Chkhartishvili N; Abutidze A; Sharvadze L; Kerashvili V; Butsashvili M; Metreveli D; Gvinjilia L; Shadaker S; Nasrullah M; Adamia E; Zeuzem S; Afdhal N; Arora S; Thornton K; Skaggs B; Kuchuloria T; Lagvilava M; Sergeenko D; Averhoff F
    Clin Infect Dis; 2020 Aug; 71(5):1263-1268. PubMed ID: 31563938
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Persistently high hepatitis C rates in haemodialysis patients in Brazil [a systematic review and meta-analysis].
    Niquini RP; Corrêa da Mota J; Bastos LS; da Costa Moreira Barbosa D; Falcão JDS; Palmieri P; Martins P; Melo Villar L; Bastos FI
    Sci Rep; 2022 Jan; 12(1):330. PubMed ID: 35013390
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Securing wider EU commitment to the elimination of hepatitis C virus.
    Wedemeyer H; Tergast TL; Lazarus JV; Razavi H; Bakoyannis K; Baptista-Leite R; Bartoli M; Bruggmann P; Buşoi CS; Buti M; Carballo M; Castera L; Colombo M; Coutinho RS; Dadon Y; Esmat G; Esteban R; Farran JC; Gillyon-Powell M; Goldberg D; Hutchinson S; Janssen HLA; Kalamitsis G; Kondili LA; Lambert JS; Marinho RT; Maticic M; Patricello A; Peck-Radosavljevic M; Pol S; Poljak M; Pop C; Sokol T; Sypsa V; Tözün N; Younossi Z; Aghemo A; Papatheodoridis GV; Hatzakis A
    Liver Int; 2023 Feb; 43(2):276-291. PubMed ID: 36196744
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatitis C disease burden and strategies for elimination by 2030 in Brazil. A mathematical modeling approach.
    Benzaken AS; Girade R; Catapan E; Pereira GFM; Almeida EC; Vivaldini S; Fernandes N; Razavi H; Schmelzer J; Ferraz ML; Ferreira PRA; Pessoa MG; Martinelli A; Souto FJD; Walsh N; Mendes-Correa MC
    Braz J Infect Dis; 2019; 23(3):182-190. PubMed ID: 31145876
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of Public Policy and COVID-19 Pandemic on Hepatitis C Testing and Treatment in France, 2014-2021.
    Brouard C; Schwager M; Expert A; Drewniak N; Laporal S; de Lagasnerie G; Lot F
    Viruses; 2024 May; 16(5):. PubMed ID: 38793673
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002.
    Seeff LB; Hoofnagle JH
    Clin Liver Dis; 2003 Feb; 7(1):261-87. PubMed ID: 12691470
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Postpartum Hepatitis C Linkage to Care Program in a Co-located Substance Use Disorders Treatment Model.
    Cheedalla A; Hinely K; Roby L; Hall OT; Malvestutto C; Rood KM
    Matern Child Health J; 2023 Dec; 27(Suppl 1):87-93. PubMed ID: 37768533
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatitis C virus infection in jail: Difficult-to-reach, not to-treat. Results of a point-of-care screening and treatment program.
    Masarone M; Caruso R; Aglitti A; Izzo C; De Matteis G; Attianese MR; Pagano AM; Persico M
    Dig Liver Dis; 2020 May; 52(5):541-546. PubMed ID: 32234417
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Micro-elimination of hepatitis C virus infection in the rural and remote areas of Taiwan - A multi-center collaborative care model.
    Lo CC; Lei WY; Huang YC; Hwang JJ; Lo CY; Lin CH; Cheng HS; Liao YT; Liang PC; Chiou MJ; Bair MJ; Dai CY; Yu ML
    J Microbiol Immunol Infect; 2023 Aug; 56(4):680-687. PubMed ID: 36822945
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Population Level Cascade of Care for Hepatitis C in British Columbia, Canada: The BC Hepatitis Testers Cohort (BC-HTC).
    Janjua NZ; Kuo M; Yu A; Alvarez M; Wong S; Cook D; Wong J; Grebely J; Butt ZA; Samji H; Ramji A; Tyndall M; Krajden M
    EBioMedicine; 2016 Oct; 12():189-195. PubMed ID: 27596150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.